Lenalidomid Zentiva

Lenalidomide, the active ingredient in Lenalidomid Zentiva, is an immunomodulatory agent presented as an oral tablet for oral use. It is employed in the treatment of certain blood cancers, including multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma, in adult patients. It is indicated for patients with relapsed or refractory disease.

GNH USA supplies Lenalidomid Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring quality assurance, regulatory compliance and reliable logistics for global distribution.

Lenalidomide is used in hematologic malignancies that involve abnormal plasma cell or lymphoid proliferation. - Multiple myeloma: reduces disease progression and improves overall survival in eligible adult patients. - Myelodysplastic syndromes with del(5q): corrects cytopenias and decreases transfusion dependence. - Mantle cell lymphoma: contributes to tumor control and prolongs remission when combined with standard chemotherapy.

Lenalidomid Zentiva may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may lead to dehydration. - Rash: mild to moderate skin eruptions. - Neutropenia: reduced neutrophil count increasing infection risk.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Secondary malignancies: emergence of new cancers during treatment.

Before initiating therapy, clinicians should evaluate patient-specific risk factors and monitor laboratory parameters. - Pregnancy testing: avoid use in pregnancy due to teratogenic risk (Category X). - Contraception: ensure effective birth control for both male and female patients of reproductive potential. - Thrombosis prophylaxis: consider anticoagulation in patients with additional risk factors. - Renal function: adjust monitoring for patients with impaired kidney function. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Lenalidomid Zentiva can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce plasma concentrations. - Anticoagulants (e.g., warfarin): increased risk of bleeding.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise drug levels. - Immunosuppressants (e.g., cyclosporine): heightened immunomodulatory effects. - Vaccines: live attenuated vaccines should be avoided during treatment.